CONCLUSIONES

De lo anterior podemos deducir, que existen numerosas herramientas terapéuticas que pueden ser empeladas en el tratamiento de esta temible complicación de la Diabetes mellitus denominada Pie diabético, todas estas variantes van a requerir la existencia de un apropiado abordaje equipo multidisciplinario que labores desde la prevención hasta la rehabilitación una vez realizada una amputación mayor de ser necesaria, se introducen nuevos conceptos relacionados con el empleo de la terapia con factores de crecimiento en el tratamiento de la ulceración del diabético, específicamente con el Heberprot P (factor de crecimiento epidérmico humano recombinante).

REFERENCIAS BIBLIOGRÁFICAS

1. Shojaie A, Esmaelzadeh M, Larijani B, Assessment and treatment of diabetic foot ulcer. Int J Clin Pract, 2007; 61(11): 1931-1938.
2. Alcala D, et. al. Desarrollo de una vía clínica para el pie diabético. Rev Calidad Asistencial, 2003; 18(4): 235-243.
3. Apelqvist J, Bakker K, van Houtum WH, et. al. International consensus and practical guidelines on the management and the prevention of the diabetic foot. Diabetes Metab Res Rev 2000; 16 (Suppl 1): S84-92.
4. Boulton AJ. The diabetic foot: a global view. Diabetes Metab Res Rev 2000; 16 (Suppl. 1): s2–5.
5. Khanolkar R, Bain S, Stephens J. The diabetic foot. QJM 2008; 101 (9): 685-695
6. Garcia Herrera A, Fernandez Montequin JI, Rodriguez Fernandez R. el Pie diabético. Elsevier España SA. Madrid 2004: 83-4
7. Boyko E, Ahroni J, Stensel V, Forsberg R, Davignon D, Smith D, A prospective study of risk factors for diabetic foot ulcer. Diabetes Care, 1999; 22(7): 1036-1042.
8. Pliskin MA, Todd WF, Edelson GW. Presentations of diabetic feet. Arch Fam Med 1994; 3: 273–9.
9. Wieman TJ. Principles of management: the diabetic foot. Am J Surg 2005; 190: 295–29.
10. Rowering CK. Diabetic foot ulcers, pathophysiology assessment and therapy. Can Fam Physician 2001; 47: 1007–16.
11. Singh N, Armstrong D, Lipsky B, Preventing foot ulcers in patients with diabetes. JAMA, 2005; 293(2):217-228.
12. Rowering CK. Diabetic foot ulcers, pathophysiology assessment and therapy. Can Fam Physician 2001; 47: 1007–16.
13. Frykberg RG. Diabetic foot ulcers: current concepts. J Foot Ankle Surg 1998; 37: 440–6.
14. Khanolkar R, Bain S, Stephens J. The diabetic foot. QJM 2008; 101 (9): 685-695.
15. Pataky Z, Herrmann F, Regat D, Vuagnat H. The at-risk foot concerns not only patients with diabetes mellitus. Gerontology 2008; 54: 349-353.
16. Genuth S, Albeti KG, Bennett P et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160.
17. Kravitz SR, Mc Guire J, Shanahan SD. Physical assessment of the diabetic foot. ADV Skin Wound Care 2003; 16: 68–77.
18. LoGerfo FW, Coffman JD. Current concepts: vascular and microvascular disease of the foot in diabetes: implication for foot care. N Engl J Med 1984; 311: 1615-9.
19. LoGerfo FW, Gibbons GW. Ischemia in the diabetic foot: modern concepts and management. Clinical Diabetes 1989: 72-5.
20. Apelqvist J, Castenfors J, Larsson J, et. al. Prognostic value of systolic ankle and toe blood pressure levels in outcome of diabetic foot ulcer. Diabetes Care 1989; 12: 373-8.
21. Emanuele MA, Buchanan BJ, Abraira C. Elevated leg systolic pressures and arterial calcification on diabetic occlusive vascular disease. Diabetes Care 1981; 4: 289-92.
22. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003; 26: 3333-41.
23. Foster A, Edmonds ME. Simple staging system: a tool for diagnosis and management. The Diabetic Foot 2000; 3: 56-62.
24. Lipsky BA, International Consensus Group on Diagnosing and Treating the Infected Diabetic Foot. Report from the International Consensus on Diagnosing and Treating the Infected Diabetic Foot. Diabetes Metab Res Rev 2004; 20 (Suppl 1): S68-77.
25. DiNubile MJ, Lipsky BA. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother 2004; 53 (Suppl 2): 37-50.
26. Eneroth M, Persson BM. Risk factors for failed healing in amputation for vascular disease. A prospective, consecutive study of 177cases. Act Orthop Scand 1993;64:369-372.
27. Castro G Guía clínica para el manejo del pie diabético Medicina Interna de México Volumen 25, núm. 6, noviembre-diciembre 2009: 526-37
28. Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJM. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 1998;21:1071–5.
29. Van Rijswijk L, Polansky M. Predictors of time to healing deep pressure ulcers. Ostomy Wound Manage 1994;40:40–8.
30. Bazley LA, Gullick WJ. The epidermal growth factor receptor family. Endocr Relat Cancer 2005;12:S17–S27.
31. Fernandez-Montequın JI, Betancourt BY, Leyva- Gonzalez G, Lopez Mola E, Galan-Naranjo K, Ramırez-Navas M, Bermudez-Rojas S, Rosales F, Garcia lglesias E, Berlanga-Acosta J, Silva-Rodriguez R, Garcia-Siverio M, Herrera Martinez L. lntralesional administration of epidermal growth factor-based formulation (Heberprot-P) in advanced diabetic foot ulcer: Treatment up to complete wound closure. Int Wound J 2009;6:67–72.
32. Berlanga J, Savigne W, Valdez C, Franco N, Alba JS, del Rio A, et al. Epidermal Growth Factor intralesional infiltrations can prevent amputation in diabetic patients with advanced foot ulcers. Int Wound J 2006;3:232–239.
33. Fernandez-Montequın JI, Infante-Cristia E, Valenzuela-Silva C, Franco-Perez N, Savigne-Gutierrez W, Artaza-Sanz H, Morejon-Vega L, Gonzalez-Benavides C, Eliseo-Musenden O, Garcıa-lglesias E, Berlanga-Acosta J, Silva-Rodriguez R, Betancourt BY, Lopez-Saura PA, for the Cuban Citoprot-P Study Group. Intralesional injections of Citoprot-P® (recombinant human Epidermal Growth Factor) in advanced diabetic foot ulcers with risk of amputation. Int. Wound J. 2007;4:333–43.
34. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998;21:822–7.
35. Heng MC, Harker J, Bardakjian VB, Ayvazian H. Enhanced healing and cost-effectiveness of low-pressure oxygen therapy in healing necrotic wounds: a feasibility syudy of technology transfer. Ostomy Wound Manage 2000; 46:52-62.
36. Bakker JD. Hyperbaric oxygen therapy and the diabetic foot. Diabetes metab Res Rev 2000, 16:1S55-58.
37. Apelqvist J, Armstrong DG, Lavery LA et al. Resource utilization and economic costs of care based on a randomized trial of vacuum-assisted closure therapy in the treatment of diabetic foot wounds. Am J Surg 2008; 195:782- 788.
38. Blume PA, Walters J, Payne W et al. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care 2008; 31:631-636.
39. Akbari A, Moodi H, Ghiasi F et al. Effects of vacuum compression therapy on healing of diabetic foot ulcers: Randomized controlled trial. J Rehabil Res Dev 2007; 44:631-636.
40. Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, Hann AW, Hussein A, Jackson N, Johnson KE, Ryder CH, Torkington R, Van Ross ER, Whalley AM, Widdows P, Williamson S, Boulton AJ; North-West Diabetes Foot Care Study. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabetic Med 2002;19:377–384.
41. Lavery LA, Armstrong DG, Vela SA, et al: Practical criteria for screening patients at a high risk of diabetic foot ulceration, Arch Intern Med Pag 158-157, 1998.
42. David G. Armstrong, Robert G. Frykberg Classifying diabetic foot surgery: toward a rational definition. Diabet Med. 2003 Apr;20(4):329-31.
43. Gavin LA. Perioperative management of the diabetic patient. Endocrinol Metab Clin North Am 1992;21:457-75.
44. Wanton O, Reyes G, Chercoles L. Rehabilitación del paciente diabético amputado por enfermedad vascular. Servicio de Angiología y Cirugía Vascular 1995. Rev Cubana Enfermer 1998; 14(2): 94-8.
45. Albuquerque V. Diabetic amputations in the VA: Are there opportunities for interventions?. J Rehabil Res Dev 1999; 36(1): 55-9´
46. Belicza G, Kullman L. Lower limb amputations during 3 years in Hungary. Arth Orthop Trauma Surg 1999; 119 (1-2): 94-7.
47. Carrera A. Sobrevida de 1 a 5 años de los pacientes amputados por pie diabético en el Hospital de Apoyo Belén de Trujillo desde 1990 hasta 1998. [Tesis para optar el grado de Bachiller en Medicina]. Trujillo: Universidad Nacional de Trujillo; 2000.
48. Humphrey A, Dowse G, Thoma, Zimmet P. Diabetes and non traumatic lower extremity amputations, Incidence, risk factors and prevention: a 12-year follow up studying Nauru. Diabetes Care 1996; 19(7): 710-4.
49. Mc Dowell D, Burns E, Young R. Problem of amputations in patients with newly diagnosed Diabetes Mellitus. Diabetic Med 1998; 15(9): 14-9.
50. Armstrong B, Lavery L, Harkless B. Treament- based classification system for assessment and care diabetic feet. J Am Pod 1996; 86(7): 311-6.
51. Ebskov B, Josephsen P. Incidence of reamputation and death after gangrene of the lower extremity. Prosthet Orthet Int 1980; 4(2): 77-80.